⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282007 | 1.00 | — | — | |
| SCHEMBL21201263 | 1.00 | — | — | |
| Iodide SCHEMBL10379495 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL31002486 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL15018854 | 0.97 | — | — | |
| Bromide SCHEMBL28845200 | 0.97 | — | — | |
| SCHEMBL778008 | 0.82 | — | — | |
| SCHEMBL19090258 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL14976758 | 0.80 | ALDH1A1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL3251015 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567543-A | Anemonin B4 derivative and preparation method and application thereof | 苏州大学 | 2024-02-20 | — | — | CN | claimed |
| CN-117567543-A | Anemonin B4 derivative and preparation method and application thereof | 苏州大学 | 2024-02-20 | — | — | CN | disclosed |
| US-20210087206-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | TURNING POINT THERAPEUTICS INC (US) | 2021-03-25 | — | — | US | disclosed |
| US-20060122224-A1 | Quinoline and quinoxaline compounds | BECHLE BRUCE M | 2006-06-08 | — | — | US | disclosed |
| US-7022686-B2 | A1 adenosine receptro antagonists | BIOGEN IDEC INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1622872-A1 | 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040204450-A1 | Quinoline and quinoxaline compounds | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
| WO-2004085401-A1 | 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20030220358-A1 | A1 adenosine receptro antagonists | BIOGEN IDEC MA INC. | 2003-11-27 | — | — | US | disclosed |
| US-6605601-B2 | Hypotensive agents; cardiovascular disorders | BIOGEN, INC. | 2003-08-12 | — | — | US | disclosed |
| US-20020111333-A1 | A1 adenosine receptor antagonists | BIOGEN IDEC MA INC. | 2002-08-15 | — | — | US | disclosed |